Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Credit agrmnt [a]
Appointed director
Pfenex Inc. (PFNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/11/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Pfenex Reports Third Quarter 2019 Results and Provides Business Update Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors study report to FDA; Commercial launch by Alvogen expected upon FDA decision on the therapeutic equivalence rating relative to Forteo®"
08/08/2019 8-K Quarterly results, Resignation/termination of a director
Docs: "Pfenex Reports Second Quarter 2019 Results and Provides Business Update",
"About Pfenex Inc."
05/09/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : May 9, 2019 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act )...",
"Pfenex Reports First Quarter 2019 Results and Provides Business Update"
03/11/2019 8-K Quarterly results
Docs: "Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update"
11/07/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : November 7, 2018 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange ...",
"Pfenex Reports Third Quarter Results and Provides Business Update"
08/08/2018 8-K Quarterly results
Docs: "PFENEX INC. Consolidated Statements of Operations"
05/10/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : May 10, 2018 Pfenex Inc. Delaware 001-36540 27-1356759 10790 Roselle Street San Diego, CA 92121 352-4400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ...",
"PFENEX INC. Consolidated Statements of Operations"
03/15/2018 8-K Quarterly results
Docs: "PFENEX INC. Consolidated Statements of Operations",
"Pfenex Inc. Investor Presentation"
11/09/2017 8-K Quarterly results
Docs: "FORM 8-K",
"PFENEX INC. Consolidated Statements of Operations"
08/09/2017 8-K Quarterly results
Docs: "FORM 8-K",
"PFENEX INC. Consolidated Statements of Operations"
05/08/2017 8-K Form 8-K - Current report
03/15/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/08/2016 8-K Quarterly results
Docs: "PFENEX INC. Consolidated Statements of Operations"
05/09/2016 8-K Quarterly results
Docs: "Pfenex Reports First Quarter 2016 Results and Provides Business Update SAN DIEGO, May 9, 2016 — Pfenex Inc. , a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the first quarter ended March 31, 2016 and provided a business update. “Pfenex continued to make solid progress in the first quarter,” stated Bertrand C. Liang, chief executive officer of Pfenex. “Today we announced the positive top-line data from our PF708 initial bioequivalence study which can be referred to in our separate press release issued this afternoon. In the second half of 2016, we expect to initiate the pivotal clinical program for PF530, our biosimilar candidate to Betaseron. Addit..."
03/10/2016 8-K Quarterly results
Docs: "Pfenex Reports Fourth Quarter and Full Year 2015 Results and Provides Business Update SAN DIEGO, March 10, 2016 — Pfenex Inc. , a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a business update. “2015 was a very productive and eventful year for Pfenex,” stated Bertrand C. Liang, chief executive officer of Pfenex. “We signed the collaboration agreement for PF582, our biosimilar candidate to Lucentis, with Hospira, now a subsidiary of Pfizer in February 2015, we led our successful secondary offering in April 2015 and we signed a significant contract with the Biomedical Advanced Rese..."
11/13/2015 8-K Quarterly results
Docs: "Pfenex Reports Third Quarter 2015 Results and Provides Business Update SAN DIEGO, November 13, 2015 — Pfenex Inc. , a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the third quarter ended September 30, 2015 and provided a business update. “Pfenex has made significant progress in advancing its portfolio of biosimilar product candidates in the third quarter,” stated Bertrand C. Liang, chief executive officer of Pfenex. “Today we are pleased to provide an update on the Phase 1 trial for PF530, our Betaseron biosimilar candidate. The study enrolled 12 subjects who received an initial dose of either PF530 or reference product to assess pharmacokinetic an..."
08/13/2015 8-K Quarterly results
Docs: "Pfenex Reports Second Quarter 2015 Results and Provides Business Update SAN DIEGO, August 13, 2015 — Pfenex Inc. , a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the second quarter ended June 30, 2015 and provided a business update. “Pfenex made significant progress in the second quarter of 2015, and we expect to provide key pipeline updates over the course of 2015 and into 2016. Specifically, we look forward to updating you on progress for PF530, our biosimilar candidate to Betaseron later in 2015 as well as on PF708, our generic to Forteo, which we expect to enter bioequivalence studies in 2H15,” stated Bertrand C. Liang, chief executive officer ..."
05/14/2015 8-K Quarterly results
Docs: "PFENEX INC. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2015 2014 Revenue $ 1,975 $ 2,558 Cost of revenue 1,308 1,908 Gross profit 667 650 Operating expense Selling, general and administrative 3,891 1,495 Research and development 2,809 678 Total operating expense 6,700 2,173 Loss from operations Other income , net 80 Net loss before income taxes Income tax expense Net loss $ $ Effective preferred stock dividends $ — $ Net loss attributable to common stockholders $ $ Net loss per common share basic and diluted $ $ Weighted-average common shares used to compute basic and diluted net loss per share 20,474 1,548 PFENEX INC. Condensed Consolidated Balance Sheets March 31, 2015 December 31, 2014"
03/16/2015 8-K Quarterly results
Docs: "Pfenex Reports Fourth Quarter and Full Year 2014 Results and Provides Business Update SAN DIEGO, March 16, 2015 — Pfenex Inc. , a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, today reported financial results for the fourth quarter and full year ended December 31, 2014 and provided a business update. “We were very pleased to have completed our IPO in July of 2014, which has allowed us to successfully advance our pipeline of biosimilar and vaccine candidates,” stated Bertrand C. Liang, chief executive officer of Pfenex. “2015 is off to an exciting start, with our announcement of the collaboration with Hospira for our lead compound, PF582, a biosimilar candidate to Lucentis on February 10..."
11/13/2014 8-K Quarterly results
Docs: "PFENEX INC. Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2014 2013 2014 2013 Revenue $ 2,801 $ 1,989 $ 8,625 $ 7,683 Cost of revenue 1,579 1,153 6,031 4,488 Gross profit 1,222 836 2,594 3,195 Operating expenses: Selling, general and administrative 2,447 1,599 5,966 5,058 Research and development 1,251 2,036 2,789 4,088 Total operating expenses 3,698 3,635 8,755 9,146 Loss from operations Other expense, net Net loss before income taxes Income tax benefit — 1,116 2,376 Net loss $ $ $ $ Effective preferred stock dividends $ — $ $ — $ Net loss attributable to common stockholders $ $ $ $ Net loss per common share basic and diluted $ $ $ $ Weighted-average common shares used to compute basic and diluted net loss per share 15,319 1,019 5,849 1,0..."
08/29/2014 8-K Quarterly results
Docs: "Pfenex Reports Second Quarter 2014 Results and Provides Business Update SAN DIEGO, August 29, 2014 — Pfenex Inc. , a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today provided a business update and reported financial results for the second quarter ended June 30, 2014. “With the successful completion of our initial public offering, we have the capital to continue to advance our biosimilar product candidates, derived from our proprietary protein expression platform,” stated Bertrand C. Liang, chief executive officer of Pfenex. “We expect to complete the phase 1b/2a trial for our lead product candidate, PF582, a biosimilar to Lucentis, by the end of 2014 and initiate the phase 3 trial in..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy